AstraZeneca to Launch Breast Cancer Drug Enhertu in India in January 2024

AstraZeneca India announced on December 21 that Enhertu will be launched in India in January 2024. Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received at least one prior systemic therapy in the metastatic setting, or who relapsed within 6 months of completing adjuvant chemotherapy or during adjuvant chemotherapy.